Thymosin Alpha-1 — The Immune Modulator

Background

Thymosin Alpha-1 (Tα1, thymalfasin) is a 28-amino-acid peptide originally isolated from bovine thymic extract by Allan Goldstein and colleagues in the 1970s. The synthetic version is marketed as Zadaxin® and is approved in over 35 jurisdictions worldwide for chronic hepatitis B and C and as an adjunctive therapy in certain cancers and immunodeficiency states.

Mechanism

Tα1 modulates both innate and adaptive immunity, promoting T-cell maturation, enhancing Th1 cytokine responses (IFN-γ, IL-2), upregulating Toll-like receptor signalling on dendritic cells, and modulating regulatory T-cell function.

What is proven

Approved use in chronic hepatitis B and C (alone or with interferon) is supported by clinical trial data in those jurisdictions. Use as an adjunctive immunostimulant in severe sepsis was studied in the multinational ETASS trials with mixed but generally positive readouts.

Tα1 has been investigated as an adjunct to chemotherapy and immunotherapy in multiple cancer types (melanoma, hepatocellular carcinoma, non-small cell lung cancer) with reported improvements in immune parameters and some survival endpoints. During the COVID-19 pandemic, observational studies and several controlled trials in China reported reduced mortality in critically ill patients receiving Tα1 — results that prompted broader research interest but did not lead to FDA approval.

What is NOT proven (in the UK/US)

Tα1 is not approved by the FDA, MHRA, EMA, or Health Canada for any indication. Use outside studied indications — including general 'immune boosting', long-COVID, post-viral fatigue, and chronic Lyme disease — lacks RCT support.

Open research questions

Definitive sepsis mortality benefit in Western trial designs; durable cancer-survival effect as an immunotherapy adjunct; specific T-cell subset effects in chronic viral infection and ageing immune systems (immunosenescence).

Regulatory status

Approved in over 35 countries including Italy, China, and several Latin American jurisdictions. Not approved by the FDA, MHRA, EMA, or TGA.

All Proteus® compounds are sold strictly for in-vitro research. Nothing on this page is medical advice, a treatment claim, or a recommendation for human use. Where compounds are licensed medicines in any jurisdiction, that approval applies to the licensed product supplied through a regulated pharmacy — not to research-grade material.